Exposure to vepafestinib resulted in dose-dependent increases in caspase 3 and 7 activity in the five lung cancer cells tested (Fig. 4b, LUAD-0002AS1, TT, ECLC5B; Extended Data Fig. 6, LC-2/ad, LUAD-0087AS2). This evidence concerns the gene CASP3 and lung carcinoma.